US 9,808,517 B2
Subunit vaccine delivery platform for robust humoral and cellular immune responses
David Putnam, Ithaca, NY (US); Joseph Rosenthal, Ithaca, NY (US); Chung-Jr Huang, Newbury Park, CA (US); Matthew Delisa, Ithaca, NY (US); and Susana Mendez, Silver Spring, MD (US)
Assigned to Cornell University, Ithaca, NY (US)
Appl. No. 14/390,948
Filed by CORNELL UNIVERSITY, Ithaca, NY (US)
PCT Filed Mar. 13, 2013, PCT No. PCT/US2013/031004
§ 371(c)(1), (2) Date Oct. 6, 2014,
PCT Pub. No. WO2013/151706, PCT Pub. Date Oct. 10, 2013.
Claims priority of provisional application 61/621,226, filed on Apr. 6, 2012.
Prior Publication US 2015/0056246 A1, Feb. 26, 2015
Int. Cl. A61K 51/00 (2006.01); A61K 39/015 (2006.01); A61K 39/04 (2006.01); A61K 39/145 (2006.01); A61K 39/35 (2006.01); A61K 39/39 (2006.01); A61K 38/16 (2006.01); A61K 39/38 (2006.01); C12N 15/70 (2006.01); A61K 39/12 (2006.01); A61K 39/00 (2006.01)
CPC A61K 39/015 (2013.01) [A61K 38/164 (2013.01); A61K 39/04 (2013.01); A61K 39/12 (2013.01); A61K 39/145 (2013.01); A61K 39/35 (2013.01); A61K 39/38 (2013.01); A61K 39/39 (2013.01); C12N 15/70 (2013.01); A61K 2039/52 (2013.01); A61K 2039/523 (2013.01); A61K 2039/6068 (2013.01); C12N 2760/16134 (2013.01)] 44 Claims
 
1. A probiotic-derived vesicle displaying a fusion protein, wherein said fusion protein comprises at least a portion of a transport protein coupled to at least a portion of one or more antigenic proteins or peptides.